Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer

Mucosal-associated invariant T (MAIT) cells constitute one of the most numerous unconventional T cell subsets, and are characterized by rapid release of Th1- and Th17-associated cytokines and increased cytotoxic functions following activation. MAIT cells accumulate in tumor tissue but show an exhaus...

Full description

Saved in:
Bibliographic Details
Main Authors: Patrik Sundström, Nikita Dutta, William Rodin, Andreas Hallqvist, Sukanya Raghavan, Marianne Quiding Järbrink
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:OncoImmunology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2024.2312631
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846142201183076352
author Patrik Sundström
Nikita Dutta
William Rodin
Andreas Hallqvist
Sukanya Raghavan
Marianne Quiding Järbrink
author_facet Patrik Sundström
Nikita Dutta
William Rodin
Andreas Hallqvist
Sukanya Raghavan
Marianne Quiding Järbrink
author_sort Patrik Sundström
collection DOAJ
description Mucosal-associated invariant T (MAIT) cells constitute one of the most numerous unconventional T cell subsets, and are characterized by rapid release of Th1- and Th17-associated cytokines and increased cytotoxic functions following activation. MAIT cells accumulate in tumor tissue but show an exhausted phenotype. Here, we investigated if immune checkpoint blockade (ICB) with antibodies to PD-1 or PD-L1 affects the function of circulating MAIT cells from non-small cell lung cancer patients. ICB increased the proliferation and co-expression of the activation markers HLA-DR and CD38 on MAIT cells in most patients after the first treatment cycle, irrespective of treatment outcome. Furthermore, production of cytokines, especially TNF and IL-2, also increased after treatment, as did MAIT cell polyfunctionality. These results indicate that MAIT cells respond to ICB, and that MAIT cell reinvigoration may contribute to tumor regression in patients undergoing immune checkpoint therapy.
format Article
id doaj-art-82e5d77d60e74f5fbca2d4e7be410777
institution Kabale University
issn 2162-402X
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series OncoImmunology
spelling doaj-art-82e5d77d60e74f5fbca2d4e7be4107772024-12-03T13:49:34ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2024.2312631Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancerPatrik Sundström0Nikita Dutta1William Rodin2Andreas Hallqvist3Sukanya Raghavan4Marianne Quiding Järbrink5Department of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SwedenDepartment of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SwedenDepartment of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SwedenDepartment of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SwedenDepartment of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SwedenDepartment of Microbiology and Immunology, Institute of Biomedicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SwedenMucosal-associated invariant T (MAIT) cells constitute one of the most numerous unconventional T cell subsets, and are characterized by rapid release of Th1- and Th17-associated cytokines and increased cytotoxic functions following activation. MAIT cells accumulate in tumor tissue but show an exhausted phenotype. Here, we investigated if immune checkpoint blockade (ICB) with antibodies to PD-1 or PD-L1 affects the function of circulating MAIT cells from non-small cell lung cancer patients. ICB increased the proliferation and co-expression of the activation markers HLA-DR and CD38 on MAIT cells in most patients after the first treatment cycle, irrespective of treatment outcome. Furthermore, production of cytokines, especially TNF and IL-2, also increased after treatment, as did MAIT cell polyfunctionality. These results indicate that MAIT cells respond to ICB, and that MAIT cell reinvigoration may contribute to tumor regression in patients undergoing immune checkpoint therapy.https://www.tandfonline.com/doi/10.1080/2162402X.2024.2312631Immune checkpoint blockadeimmunotherapyMAIT cellnon-small cell lung cancerPD-1
spellingShingle Patrik Sundström
Nikita Dutta
William Rodin
Andreas Hallqvist
Sukanya Raghavan
Marianne Quiding Järbrink
Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer
OncoImmunology
Immune checkpoint blockade
immunotherapy
MAIT cell
non-small cell lung cancer
PD-1
title Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer
title_full Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer
title_fullStr Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer
title_full_unstemmed Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer
title_short Immune checkpoint blockade improves the activation and function of circulating mucosal-associated invariant T (MAIT) cells in patients with non-small cell lung cancer
title_sort immune checkpoint blockade improves the activation and function of circulating mucosal associated invariant t mait cells in patients with non small cell lung cancer
topic Immune checkpoint blockade
immunotherapy
MAIT cell
non-small cell lung cancer
PD-1
url https://www.tandfonline.com/doi/10.1080/2162402X.2024.2312631
work_keys_str_mv AT patriksundstrom immunecheckpointblockadeimprovestheactivationandfunctionofcirculatingmucosalassociatedinvarianttmaitcellsinpatientswithnonsmallcelllungcancer
AT nikitadutta immunecheckpointblockadeimprovestheactivationandfunctionofcirculatingmucosalassociatedinvarianttmaitcellsinpatientswithnonsmallcelllungcancer
AT williamrodin immunecheckpointblockadeimprovestheactivationandfunctionofcirculatingmucosalassociatedinvarianttmaitcellsinpatientswithnonsmallcelllungcancer
AT andreashallqvist immunecheckpointblockadeimprovestheactivationandfunctionofcirculatingmucosalassociatedinvarianttmaitcellsinpatientswithnonsmallcelllungcancer
AT sukanyaraghavan immunecheckpointblockadeimprovestheactivationandfunctionofcirculatingmucosalassociatedinvarianttmaitcellsinpatientswithnonsmallcelllungcancer
AT mariannequidingjarbrink immunecheckpointblockadeimprovestheactivationandfunctionofcirculatingmucosalassociatedinvarianttmaitcellsinpatientswithnonsmallcelllungcancer